Market Research Future published a half cooked research report on “Global Actinic
Keratosis Treatment Market Research Report - Forecast to 2022” Market Analysis, Scope,
Stake, Progress, Trends and Forecast to 2022.
Cancer is becoming one of the major problems across the globe. In more than 90% cases
skin cancer is caused due to exposure to ultraviolet radiation from the sun. There are three
major type of skin cancer namely basal cell skin cancer (BCC), squamous-cell skin cancer
(SCC) and melanoma. Exposure to the radiation during childhood can cause melanomas and
basal-cell cancers. People with light skin are at higher risk for skin cancer.
Also known as solar keratosis, actinic keratosis is a type of skin cancer in which the skin
gets rough and develops scaly patches as a result of exposure to the sun. It’s most
commonly found on face, lips, ears, back of hands, forearms, and scalp or neck.
The global skin cancer market is driven by increasing prevalence of skin cancer, rising
healthcare expenditure in developing economies and increasing government support. While
adverse effect associated with treatment, long approval time for the drugs and strict
regulatory rules has restrained the growth of the market.
According to the World Health Organization (WHO), the prevalence of skin cancer is
increasing at a rate of 6.52%. Beside this continuous increasing demand for better
treatment and increasing government support for R&D has provided fuel for the growth of
market.
According to the American Academy of Dermatology (AAD), skin diseases affects one in
every fourth American. The prevalence of skin diseases is also found to be increasing in
Canada. According to Skin Cancer Foundation Statistics, one in every five Americans will
develop skin cancer in their lifetime.
Key Players in the Actinic Keratosis Market:
LEO Pharma Inc., Clinuvel Pharmaceuticals Ltd, Biofrontera AG, DUSA Pharmaceuticals,
Inc., TOLMAR Pharmaceuticals, Inc., Valeant, Galderma S.A., Perrigo Company plc. are key
player in the market. Well established players incorporate acquisition, collaboration,
partnership, expansion, and product launch in order to gain competitive advantage in this
market and to maintain their market position.
Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/2366 .
Developments of key players:
Galderma:
Galderma is a global leader in dermatology and has strategic partnerships with brands like
Soolantra, Tri-Luma, Loceryl, BenzacEpiduo, Oracea, Differin, Mirvaso, Cetaphil, Excipial,
Daylong, Restylane, Emervel and many other brands. The company focus on the production
of innovative solutions in the field of dermatology for the treatment of various skin diseases
such as acne, rosacea, psoriasis, steroid-responsive dermatoses, onychomycosis,
pigmentary disorders, skin cancer and other various fields in skin care.
January 2017: Galderma launched two new dermal fillers. In December, Galderma received
FDA approval for a pair of next-generation hyaluronic acid (HA) dermal fillers: Restylane
Refyne and Restylane Defyne.
January 2017: Galderma announces approval of Azzalure in Europe for treatment of lateral
canthal lines in adults. Azzalure, a product in-licensed from Ipsen, received positive opinion
from the French regulatory authority, ANSM, for treatment of lateral canthal lines (crow’s
feet), either alone or in combination with treatment of Glabellar lines.
July 2016: Chugai and Galderma Announce Global License Agreement for Nemolizumab
(CIM331), Novel Biologic for Skin Diseases. The primary aim of this agreement is to improve
atopic dermatitis by breaking the itch-scratch cycle which has great expectation for
Nemolizumab.
January 2016: Maruho and Galderma to Join Forces in a Strategic Alliance in Japan. One of
the major reasons of this strategic alliance is that Galderma will permit Maruho to
additionally promote their products in japan in the field of dermatology of medicines for
infectious disease, which include systemic fungal infections.